Skip to main
BCRX
BCRX logo

BioCryst Pharmaceuticals (BCRX) Stock Forecast & Price Target

BioCryst Pharmaceuticals (BCRX) Analyst Ratings

Based on 21 analyst ratings
Buy
Strong Buy 43%
Buy 52%
Hold 5%
Sell 0%
Strong Sell 0%

Bulls say

BioCryst Pharmaceuticals Inc. has demonstrated significant growth, with Orladeyo sales reaching $124 million in 4Q24, reflecting a 37% year-over-year increase, and the company has raised its 2025 revenue guidance to a range of $535 million to $550 million, indicating strong momentum. Physician sentiment toward Orladeyo has notably improved, with 59% of physicians now extremely likely to prescribe the treatment, suggesting a favorable outlook for market penetration and sales growth. The favorable reimbursement dynamics, coupled with sustained efficacy and tolerability of Orladeyo, support the expectation of reaching $1 billion in peak worldwide sales, further enhancing the company’s growth potential in the biotechnology sector.

Bears say

BioCryst Pharmaceuticals Inc. faces a negative outlook primarily due to ongoing financial losses, having reported a net loss of $26.8 million in the fourth quarter of 2024 and $88.9 million for the fiscal year 2024, indicating that profitability remains out of reach for the foreseeable future. Additionally, the company's anticipated flat to lower sales of Orladeyo in 1Q24 and projected revenue decline in 1Q25 due to patient reauthorization issues highlight significant challenges in maintaining revenue streams. Furthermore, potential risks such as failures in clinical trials, regulatory setbacks, and a limited commercial opportunity contribute to a cautious investment thesis regarding the company's long-term financial viability.

BioCryst Pharmaceuticals (BCRX) has been analyzed by 21 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 52% recommend Buy, 5% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BioCryst Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BioCryst Pharmaceuticals (BCRX) Forecast

Analysts have given BioCryst Pharmaceuticals (BCRX) a Buy based on their latest research and market trends.

According to 21 analysts, BioCryst Pharmaceuticals (BCRX) has a Buy consensus rating as of Jul 23, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15.29, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15.29, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BioCryst Pharmaceuticals (BCRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.